Semax comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide (ACTH fragment analog) | Not a steroid; does not belong to the melanocortin agonist drugs by marketing category |
| Molecular formula | C37H51N9O10S (commonly cited) | Reported values vary slightly with salt and counter-ion content |
| Appearance | White to off-white lyophilized powder | A single batch may appear as a loose cake or fluffy solid |
| Solubility | Freely soluble in water and aqueous buffer | Stock solutions are usually prepared in sterile water or saline |
| Typical storage | −20 °C or below, desiccated and protected from light | Seal opened vials promptly to limit moisture uptake |
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
The Soviets designed their first human space capsule using the same spacecraft bus as their Zenit spy satellite, forcing them to keep the details and true appearance secret until after the Vostok program was over. The craft consisted of a spherical descent module with a mass of 2.46 tonnes (5,400 lb) and a diameter of 2.3 meters (7.5 ft), with a cylindrical inner cabin housing the cosmonaut, instruments, and escape system; and a biconic instrument module with a mass of 2.27 tonnes (5,000 lb), 2.25 meters (7.4 ft) long and 2.43 meters (8.0 ft) in diameter, containing the engine system and propellant. After reentry, the cosmonaut would eject at about 7,000 meters (23,000 ft) over the USSR and descend via parachute, while the capsule would land separately, because the descent module made an extremely rough landing that could have left a cosmonaut seriously injured. The "Vostok spaceship" was first displayed at the July 1961 Tushino air show, mounted on its launch vehicle's third stage, with the nose cone in place concealing the spherical capsule. A tail section with eight fins was added in an apparent attempt to confuse western observers. This also appeared on official commemorative stamps and a documentary. The Soviets finally revealed the true appearance of their Vostok capsule at the April 1965 Moscow Economic Exhibition.
All the alkali metals react vigorously or explosively with cold water, producing an aqueous solution of a strongly basic alkali metal hydroxide and releasing hydrogen gas. This reaction becomes more vigorous going down the group: lithium reacts steadily with effervescence, but sodium and potassium can ignite, and rubidium and caesium sink in water and generate hydrogen gas so rapidly that shock waves form in the water that may shatter glass containers. When an alkali metal is dropped into water, it produces an explosion, of which there are two separate stages. The metal reacts with the water first, breaking the hydrogen bonds in the water and producing hydrogen gas; this takes place faster for the more reactive heavier alkali metals. Second, the heat generated by the first part of the reaction often ignites the hydrogen gas, causing it to burn explosively into the surrounding air. This secondary hydrogen gas explosion produces the visible flame above the bowl of water, lake or other body of water, not the initial reaction of the metal with water (which tends to happen mostly under water). The alkali metal hydroxides are the most basic known hydroxides. Recent research has suggested that the explosive behavior of alkali metals in water is driven by a Coulomb explosion rather than solely by rapid generation of hydrogen itself. All alkali metals melt as a part of the reaction with water. Water molecules ionise the bare metallic surface of the liquid metal, leaving a positively charged metal surface and negatively charged water ions.
=== Cold mixed absinthe === Many modern absinthes are produced using a cold-mix process. This inexpensive method of production does not involve distillation, and is regarded as inferior for the same reasons that give cause for cheaply compounded gin to be legally differentiated from distilled gin. The cold mixing process involves the simple blending of flavouring essences and artificial colouring in commercial alcohol, in similar fashion to most flavoured vodkas and inexpensive liqueurs and cordials. Some modern cold-mixed absinthes have been bottled at strengths approaching 90% ABV. Others are presented simply as a bottle of plain alcohol with a small amount of powdered herbs suspended within it. The lack of a formal legal definition in most countries to regulate the production and quality of absinthe has enabled cheaply made products to be falsely presented as traditional in production and composition. In Switzerland, the only country with a formal legal definition of absinthe, any absinthe product not obtained by maceration and distillation or coloured artificially cannot be sold as absinthe.
==== Ovarian production ==== Progesterone is the major progestogen produced by the corpus luteum of the ovary in all mammalian species. Luteal cells possess the necessary enzymes to convert cholesterol to pregnenolone, which is subsequently converted into progesterone. Progesterone is highest in the diestrus phase of the estrous cycle.
Hit to lead (H2L) also known as lead generation is a stage in early drug discovery where small molecule hits from a high throughput screen (HTS) are evaluated and undergo limited optimization to identify promising lead compounds. These lead compounds undergo more extensive optimization in a subsequent step of drug discovery called lead optimization (LO). The drug discovery process generally follows the following path that includes a hit to lead stage:
Sources: en.wikipedia.org
== Electrospray and atmospheric pressure chemical ionization == Electrospray and atmospheric pressure chemical ionization have different rules for spectrum interpretation due to the different ionization mechanisms. Fragmentation behavior is different too.
Seaport terminals handle a wide range of maritime cargoes. Break bulk / general cargo are goods that are handled and stowed piecemeal to some degree, as opposed to cargo in bulk or modern shipping containers. They are typically bundled in batches for hoisting, (with cargo nets, slings or crates), or stacked on trays, pallets or skids. They are generally lifted directly into and out of a vessel's holds, by cranes or derricks present on the dock or on the ship itself. If hoisted onto the deck instead of straight into the hold, cargo then is manhandled and stowed by stevedores. Securing break bulk and general freight inside a vessel includes the use of dunnage. When no hoisting equipment is available, break bulk would previously be man-carried on and off the ship, over a plank, or by passing via human chain. Since the 1960s, the volume of break bulk cargo has enormously declined worldwide in favour of mass adoption of containers. Bulk cargo, such as salt, oil, tallow, but also scrap metal, is usually defined as commodities that are neither on pallets nor in containers. Bulk cargoes are not handled as individual pieces, the way heavy-lift and project cargo are. Alumina, grain, gypsum, logs, and wood chips, for instance, are bulk cargoes. Bulk cargo is classified as liquid or dry.
October 23, 2009: United Kingdom The UK markets had contracted by 0.4% in the third quarter against what was expected to be a period of growth, as a result of unexpectedly poor performance by the service sector.
==== Wet spinning ==== Wet-spinning, introduced with rayon fiber production, involves dissolving polymers in a suitable solvent before extrusion. Unlike dry-spinning, the solvent need not be volatile. During wet-spinning, the polymeric solution is extruded through a spinneret into a coagulation bath, leading to a phase inversion and precipitation. Natural and synthetic polymers, including gelatin, alginate, collagen, and cellulose, are processed into fibers via wet-spinning for various tissue engineering applications. This technique enables the production of fibers with large diameters and architectures with high porosity and interconnected open pore structures, facilitating cell penetration, adhesion, and proliferation.
Sources: en.wikipedia.org
The UV-inactivated SeV (and likely the alive virus as well) can stimulate dendritic cells to secrete chemokines and cytokines such as interleukin-6, interferon-beta, chemokine (C-C motif) ligand 5, and chemokine (C-X-C motif) ligand 10. These molecules activate both CD8+ T cells as well as natural killer cells. UV-inactivated SeV triggers the production of an intercellular adhesion molecule-1 (ICAM-1, CD54), which is a glycoprotein that serves as a ligand for macrophage-1 antigen (Mac-1) and lymphocyte function-associated antigen 1 (LFA-1 (integrin)). This induced production happens through the activation of NF-κB downstream of the mitochondrial antiviral signaling pathway and the RIG-I. The increased concentration of ICAM-1 on the cells surface increases the vulnerability of these cells to natural killer cells. It has been shown in the Namalwa cells that SeV virus stimulates an expression of many genes involved in immune defense pathways, such as type I and type II IFN signaling, as well as cytokine signaling. Among the ten most virus-induced mRNAs are IFNα8, IFNα13, IFNβ, IFNλ: (L28α, IL28β, IL29), OASL, CXCL10, CXCL11 and HERC5.
Renovo Group plc was a biopharmaceutical company founded in 1998 and headquartered in Manchester, United Kingdom. It worked in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration. Renovo does not currently have any marketed products. It aimed "to be first to market with a scar prevention pharmaceutical drug in the US and Europe" in approximately 2014. Following the failure of its last clinical candidate, Juvista, all 100 of Renovo's staff were laid off in 2011. Although the company stopped all pharmaceutical development, it continued as a financial provider. In August 2014, Renovo Group plc was renamed Inspired Capital plc.
=== Burger technique === The restaurant's burgers are created using chopped Angus beef chuck steak cut into thin slices. Fast food restaurants more typically use ground beef to form burger patties. It also markets its meat as "fresh, never frozen" and the beef is transported in 10-pound (4.5 kg) portions from distribution sites to restaurants each morning. There, employees divide the beef into loosely packed meatballs by hand. The burger meatball contains a bouillon-like flavoring and it is also seasoned with a proprietary blend that includes kosher salt, black pepper, and garlic, shortly before cooking. Meanwhile, the burger buns are made using a compression toaster and butter wheel so that they do not become too soggy once a patty is placed on them.
Sources: en.wikipedia.org
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.
It was developed in the Soviet Union during the early 1980s by groups at the Institute of Molecular Genetics in Moscow. Russian approval for intranasal use followed, and it has been marketed there since. Western laboratories encountered it mainly through translated literature and, later, through online research-chemical trade.
It holds a Russian registration as a prescription nasal product but has no approval from the European Medicines Agency or the United States Food and Drug Administration. Buyers outside Russia usually receive material sold strictly for laboratory research. That distinction matters because research-grade and pharmaceutical-grade products carry different documentation and testing expectations.
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.